MedImmune boosts cancer R&D pipeline with potential $440M Spirogen buy

10/15/2013 | Reuters

AstraZeneca's MedImmune unit agreed to acquire Spirogen, a privately held biotech firm focused on antibody-drug conjugate technology, for $200 million upfront plus $240 million in milestone fees as part of efforts to strengthen its oncology research and development pipeline. The agreement includes a $20 million equity investment in Switzerland's ADC Therapeutics, which has a licensing deal with Spirogen. ADC's and Spirogen's technologies will allow MedImmune to "accelerate antibody-drug conjugates into the clinic," MedImmune Executive Vice President Bahija Jallal said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR